We are thrilled with the exceptional pre-clinical efficacy shown in the CT-01 and CT-03 projects as we take these programs to the clinic to provide superior care for cancer patients. Said: “The field of Targeted Protein Degradation is advancing rapidly, with 18 degraders currently in clinical development to address life-threatening and life-impairing diseases. Michał Walczak, CSO of Captor Therapeutics, Fully exploit the partnering opportunities that these technology developments provide.īuild on Captor's solid European listing and investor base to attract US investors, potentially culminating in a US NASDAQ presence (through an ADR or direct listing), subject to favorable capital market conditions. Platform through degrading targets with high clinical potential by leveraging Captor's novel E3 ligase ligands and expanding the use of high potency degraders into the antibody drug conjugate space. Proof of efficacy in 2023 as a prelude to collaborative development. Initiate the clinical development by Captor of its advanced projects CT-01 (Hepatocellular carcinoma) and CT-03 (haematological malignancies) in 20 respectively, with clinical data readouts in 20.Īdvance Captor's early pipeline assets in inflammation (CT-02, CT-05) to The main strands to the 2023-2025 plan are: We look forward to embarking on this journey with our current and future partners and shareholders.” We have set an ambitious plan to fast forward the development of our pipeline and take two assets into the clinic, balancing risk and reward and allowing maximal growth in company value. Since our IPO in 2021, these advances have allowed Captor to come through the recently challenging Biotech market much better than most European and US Biotech companies. Said: “We have made great progress with taking our highly differentiated pipeline toward the clinic, keeping our TPD platform at the cutting edge of developments in the field, and signing a major strategic collaboration.

Tom Shepherd, CEO of Captor Therapeutics, to develop novel degraders against a neurodegeneration target.ĭr. Platform were further validated by the signature late last year of a significant collaboration with Ono Pharmaceutical Co., Ltd. Platform, recent breakthroughs related to the development of high affinity ligands targeting novel E3 ubiquitin ligases, understanding these ligases’ 3D architecture at high resolution atomic level, and new highly potent degraders (pico-molar degradation potency), are laying the foundation for a next generation degrader pipeline. Captor's fully-owned lead assets are in IND-enabling studies and have both demonstrated compelling efficacy in animal models of hepatocellular cancer and haematological malignancies respectively. The 2023-2025 plan builds on the excellent progress made over the last 18 months with Captor’s two lead pipeline assets as well as major advances in the Optigrade (“Captor”) (WSE:CTX), a leader in the development of Targeted Protein Degradation (TPD)-based drugs, today announced its strategic objectives for the period 2023 to 2025 aimed at building a clinical stage, major international player in the rapidly growing TPD space. Our multidisciplinary competences enable us to capitalize on the latest scientific advancements, selecting the most promising targets and developing degraders with excellent druggable properties.WROCŁAW, Poland, Ma(GLOBE NEWSWIRE) - Captor Therapeutics S.A. With our Optigrade TM platform, we strive to expedite the drug discovery process and deliver clinical candidates that have a significant impact on patients' lives. Our expertise in proteomics and structural biology, combined with the latest technologies and interdisciplinary approaches, positions us strongly to address unmet medical needs and develop highly promising therapies. We enhance our target validation and drug screening capabilities through precise genome editing using CRISPR/Cas9 tools. Through targeted protein degradation, we carefully select optimal target-ligase pairs, allowing us to rapidly identify lead-quality molecules. Our platform incorporates industry-leading protein engineering, structural biology, and molecular modelling that enables structure-guided optimization of our lead compound series. Captor Therapeutics' Optigrade™ platform is a powerful drug discovery engine.Īt Captor, we leverage cutting-edge technologies and multidisciplinary expertise to quickly identify and develop novel drugs that target high-value therapeutic areas.

Captor therapeutics